Metabolic syndrome, insulin resistance and adiponectin level in patients with chronic hepatitis C

Journal of Gastrointestinal and Liver Diseases

Volumn 17, Issue 2, 2008, Pages 147-154

  Grigorescu, Mircea ^a   Radu, Corina ^a   Crişan, Dana ^a   Dan Grigorescu, Mircea ^a   Şerban, Alexandru ^b   Neculoiu, Dana ^c   Rusu, Margareta ^b   Acalovschi, Monica ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Emergency Universitary Hospital   (Romania)

^c Clinic County Emergency Hospital   (Romania)

Author keywords

Chronic hepatitis C; Insulin resistance; Metabolic syndrome; Sserum adiponectin

Indexed keywords

ADIPONECTIN; C PEPTIDE; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CALCULATION; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORPHOMETRICS; MULTIPLE LINEAR REGRESSION ANALYSIS; PREDICTOR VARIABLE; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; BIOLOGICAL MARKERS; BIOPSY; BLOOD GLUCOSE; BODY MASS INDEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 46449103512     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Koike K. Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH. Hepatol Res 2005; 33: 145-150.
2. Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 2004; 41: 132-138.
3. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-1008.
4. Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G. Review article: hepatitis C virus-associates steatosis - pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 2005; 22(suppl 2]: 52-55.
5. Lecube A, Hernandez C, Simó R, Estcban JI, Genesca J. Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Am J Gastroenterol 2007; 102:2189-2195.
6. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599.
7. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral - related steatosis. FASEB J2002; 16: 185-194.
8. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-597.
9. Camma C, Bruno S, DiMarco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43: 64-71.
10. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C infection and fibrosis progression. Gastroenterology 2003; 125: 1695-1704.
11. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45: 80-87.
12. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
13. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-1272.
14. Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001; 35: 307.
15. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobctalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-434.
16. Poynard T, Ratziu V, McHutchinson J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
17. Matsuzawa Y, Funahashi T, Kihara S, Shimowura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
18. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006; 101: 2629-2640.
19. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54: 303-306.
20. Cua IHY, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007; 46: 66-73.
21. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org. May 2005
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
23. Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12: 7075-7080.
24. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperation Study Group. Hepatology 1994; 20: 15-20.
25. Cholet F, Nousbaum JB, Richecoeur M, et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol 2004; 28: 272-278.
26. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
27. WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization, 1999, report No WHO/NCD/NCS/99.2.
28. Grundy SM. Metabolic syndrome: part II. Endocrinol Metab Clin North Am 2004; 33: xi-xiii.
29. Sanyal AJ. Review article: non-alcoholic fatty liver disease and hepatitis C - risk factors and clinical implications. Aliment Pharmacol Ther 2005; 22(suppl 2]: 48-51.
30. Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35: 279-283.
31. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T; LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003; 39: 1049-1055.
32. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklchaimanot S, Akhtar AJ. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey (NHANES III]. Diabetes Res Clin Pract 2007; 75: 320-326.
33. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-l/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-1392.
34. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of supprcssor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508.
35. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848.
36. Moucari R, Asselah T, Cazals-Hatcm D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level and liver fibrosis. Gastroenterology 2008; 134: 416-423.
37. Hsu CS, Liu CJ, Liu CH, et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008; 28:271-277.
38. Yoneda M, Saito S, Ikeda T, ct al. Hepatitis C virus directly associated with insulin resistance independent of the visceral fat area in nonobesc and nondiabetic patients. J Viral Hepat 2007; 14: 600-607.
39. Durante-Mangoni E, Zampino R, Marrone A, ct al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006; 24: 1349-1357.
40. Lo Iacono O, Venezia G, Petta S, ct al. The impact of insulin resistance, scrum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007;25: 1181-1191.
41. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006; 12: 6756-6765.
42. Ratziu V, Trabut JB, Poynard T. Fat, diabetes and liver injury in chronic hepatitis C. Curr Gastroentcrol Rep 2004; 6: 22-29.
43. Liu CJ, Jcng YM, Chen PJ, et al. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. Antivir Ther 2005; 10: 405-415.
44. Czaja MJ. Liver injury in the setting of steatosis: crosstalk between adipokinc and cytokinc. Hcpatology 2004; 40: 19-22.
45. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005; 22(suppl2]:3-10.
46. Jonsson JR, Moschcn AR, Hickman IJ, ct al. Adiponcctin and its receptors in patients with chronic hepatitis C. J Hepatol 2005; 43: 929-936.
47. Ratziu V, Sabouri M, Poynard T. Worsening of steatosis and fibrosis progression. Gut 2003; 53: 1386-1387.
48. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002; 51: 1319-1336.
49. Zylberberg H, Rimaniol AC, Pol S, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999; 30: 185-191.
50. Iannucci CV, Capoccia D, Calabria M, Leonetti F. Metabolic syndrome and adipose tissue: new clinical aspects and therapeutic targets. Curr Pharm Des 2007; 13: 2148-2168.
51. Guerre-Millo M. Adiponectin: an update. Diabetes Metab 2008; 34: 12-18.
52. Pittas AG, Joseph NA, Greenbcrg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004; 89: 447-452.
53. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver disease in mice. J Clin Invest 2003; 112: 91-100.
54. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokinc Netw 2006; 17: 4-12.
55. Petit JM, Mincllo A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus infected patients. J Clin Endocrinol Metab 2005; 90: 2240-2243.
56. Siagris D, Vafiadis G, Michalaki M, et al. Serum adiponectin in chronic hepatitis C and B. J Viral Hepat 2007; 14: 577-583.
57. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hcpatology 2005; 42: 987-1000.
58. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokinc interplay and regulation of insulin resistance. Gastroenterology 2006; 131: 934-945.
59. Liu CJ, Chen PJ, Jeng YM, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005; 43: 235-242.
60. Tai TY, Lu JY, Chen CL, et al. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 2003; 178: 457-465.
61. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP] Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III]. JAMA 2001; 285: 2486-2497.